Precision Oncology's Breakout Week: New Pills Target Breast Cancer Mutations and Pancreatic Cancer's 'Undruggable' Protein

The FDA approved Eli Lilly's oral combination of Inluriyo (imlunestrant) and Verzenio (abemaciclib) for advanced breast cancers carrying the ESR1 mutation, doubling median progression-free survival from 5.5 months to 11.1 months in trial participants. A simple blood test can now identify eligible patients — making this a textbook win for precision oncology. As Memorial Sloan Kettering's Dr. Komal Jhaveri noted, oncologists had already been prescribing the combo off-label; FDA...